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Summary Keloids have high recurrence rates. Current ﬁrst-line therapy is triamcinolone (TAC) 
injection, but it has been suggested that approximately 50% of keloids are steroid resistant. 
We compared the efﬁcacy of intralesional 5-ﬂuorouracil (5-FU) and triamcinalone injections 
in a double-blind randomized controlled trial. Forty-three patients with 50 keloid scars were 
treated with either intralesional TAC or 5-FU-injections over 6 months. 
There was no statistically signiﬁcant difference in the remission rate at 6 months between 
the 5-FU and TAC groups (46% vs 60%, respectively). Local adverse effects were higher in the 
TAC group compared to the 5-FU group. Occurrence of skin atrophy in TAC group was 44% and 
in the 5-FU group 8% (p < 0.05). Also the occurrence of telangiectasia in the TAC group was 
50% and in the 5-FU 21% (p < 0.05). Vascularity of the keloids, assessed by spectral imaging 
and immunohistochemical staining for blood vessels, after treatment decreased in the TAC 
group, but not in the 5-FU group (p < 0.05). Fibroblast proliferation evaluated by Ki-67 staining 
signiﬁcantly decreased in the TAC group (p < 0.05) but increased in the 5-FU group (p < 0.05). 
TAC and 5-FU injections did not differ in their clinical effectivity in this randomized study, 
but 5-FU injections lead to increased proliferation rate and did not affect vascular density 
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in histological assessment. Due to the greater number of adverse effects observed after TAC 
treatment, 5-FU injections may be preferable for cosmetically sensitive skin areas. 
© 2018 British Association of Plastic, Reconstructive and Aesthetic Surgeons. Published by El- 
sevier Ltd. All rights reserved. 
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tntroduction 
reatment of keloid scars is challenging for clinicians. De- 
pite several reported strategies, no standard treatment 
rotocol exists. 1,2 Triamcinolone acetate (TAC) injections 
re considered as the ﬁrst treatment option for keloids. 1 
he efﬁcacy of TAC in keloid treatment has been demon-
trated in clinical trials already in the 1960s and 1970s. 3 –5 
ased on these earlier trials, it has been estimated that TAC
hows clinical effect in the majority of treated keloids. 6 
owever, more recent data suggests that up to 50% of
eloids do not respond to steroid injections. 7,8 Furthermore, 
–50% of keloids that initially respond to TAC treatment ul-
imately relapse. 7 In addition to quite high proportions of 
eloids either not responding to TAC or developing recur- 
ence, approximately half of the TAC treated keloids are 
lso associated with side effects such as subcutaneous at- 
ophy and telangiectasia. 1 Thus new therapeutic options, 
mong them antineoplastic agent 5-ﬂuorouracil (5-FU) have 
merged as a potential option to improve treatment efﬁ- 
acy without adverse effects. 5-FU is a ﬂuorinated pyrimi- 
ine antimetabolite that inhibits ﬁbroblast proliferation. 1,9 
 possible mechanism of action of 5-FU is the selective 
lockage of collagen synthesis by keloid ﬁbroblasts. 9,10 
Preliminary studies comparing 5-FU with TAC have been 
imited and failed to provide conclusive evidence of efﬁ- 
acy. 11,12 The aim of this study was to compare the efﬁcacy
nd possible side effects of TAC and 5-FU injections for the
reatment of keloids in a double-blind, randomized, con- 
rolled trial. 
atients and methods 
he study was approved by the Ethics Committee of 
he Pirkanmaa Health Care District and recorded in the 
rospective clinical studies database: ClinicalTrials.gov 
#NCT02155439). 
Initially, 105 patients with previously treated keloid scars 
ere seen at the outpatient clinic. A total of 43 patients
ith 50 active and symptomatic keloid scars requiring treat- 
ent were enrolled and randomized into two groups. All 
atients were counseled about the study design and given 
he option to enroll. After initial screening and a cooling 
ff period, patients who enrolled provided consent to the 
tudy. Some keloids were treated for ﬁrst time ( Table 1 ).
 keloid was deﬁned as a scar growing outside the bound-
ries of the original wound without signs of resolution over 3
ears. Inclusion criteria of this study were: any patient over 
8 years of age undergoing keloid treatment in Tampere 
niversity Hospital and suitable for treatment with drug in- 
ections (Supplemental Figure Consort 2010 ﬂow diagram). 
he exclusion criteria of this study excluded: patients under 
he age of 18, pregnancy or planned pregnancy, lactation, enal failure, liver dysfunction, hematological disease or 
one marrow suppression, systemic or local infection. The 
auses and anatomical sites of the keloids are shown in
able 1 . 
A permutated-block randomization with closed en- 
elopes was used to ensure equal group sizes, leading to
 groups, each with 25 keloid scars. Each randomized selec-
ion of envelope was performed blindly by the same plastic
urgeon (the senior author) who also performed the drug in-
ections without revealing the patient allocation (i.e. drug 
reatment to the patients). The response to therapy was as-
essed independently by another plastic surgeon (the ﬁrst 
uthor). The patient and observer were blinded at the time
he outcome was assessed. Follow up was performed at 6
onths. By that time all of the data had been analyzed
n single blinded fashion. The plastic surgeon performing 
he injections did not perform any analysis of collected
ata. 
The patients were treated with intralesional injections 
f either TAC or 5-FU. All the patients were reviewed in for
ollow up assessment a total of ﬁve times (once every 3–4
eeks until week 12 and at 6 months). 
The injections were given during the ﬁrst three visits by
he same senior plastic surgeon, who alone knew the re-
ult of randomization. The injections were given according 
o the published recommendations. Injection technique was 
qual as described in previous papers, i.e. under local anes-
hesia, either TAC or 5-FU was injected from several direc-
ions directly into the keloid with care taken not to inject
nder the keloid mass or too close to epidermis to avoid
nnecessary local side effects. The injectable was intro- 
uced into the scar until blanching occurred. For patients
ho responded well and did not need three injections,
ontrol visits were carried out without further injections 
 Table 2 ). There were no placebo injections, i.e. the pa-
ients were randomized into two groups having either TAC
r 5-FU injections. 
For TAC injections, Lederspan® (Haupt Pharma Wolfrat- 
hausen GmbH, Germany) 20 mg/ml mixed 1:1 with lido-
aine 10 mg/ml (Orion Pharma, Finland) was used. For 5-FU
njections, 5-Fluorouracil Accord® (AccordHealthCare Ltd 
orth Harrow, UK) was used at a concentration of 50 mg/ml.
oth groups received local anesthesia with lidocaine ﬁrst. 
-FU cannot be mixed with lidocaine, as it is a cytostatic
nd prepared in the hospital pharmacy. However, TAC can
e uniformly administered mixed with a local anesthetic, 
ence we used it in this way. 
A blinded observer (the ﬁrst author) assessed the keloids 
sing a validated scar scale, the Patient and Observer Scar
ssessment Scale (POSAS) and objective assessment was 
erformed with a spectrocutometer camera. 13 Keloids were 
eparately assessed and evaluated for evidence of skin 
trophy and telangiectasia as adverse effects after both 
reatments. Each patient ﬁlled out the patient component 
6 K. Hietanen et al. 
Table 1 Demographics. 
Characteristic TAC (n = 25) 5-FU (n = 25) P 
Age, years ND ∗∗
Median 40 43 
Mean 41 46.96 
Range 18–77 21–81 
Sex, n(%) ND ∗
Male 11 (44%) 15 (60%) 
Female 14 (56%) 10 (40%) 
Anatomic 
Location n (%) ND ∗
Chest 6 (24%) 9 (36%) 
Shoulder 6 (24%) 6 (24%) 
Upper back 10 (40%) 1 (4%) 
Abdomen 3 (12%) 4 (16%) 
Etiology ND ∗
Surgery 13 (52%) 12 (48%) 
Acne 7 (28%) 6 (24%) 
Trauma 2 (8%) 4 (16%) 
Unknown 2 (8%) 1 (4%) 
Vaccination 1 (4%) 0 (0%) 
Burn injury 0 (0%) 1 (4%) 
Piercing 0 (0%) 1 (4%) 
Previous treatments ND ∗
None 8 (32%) 8 (32%) 
TAC 15 (60%) 15 (60%) 
5-FU 1 (4%) 1 (4%) 
Radiation and surgery 1 (4%) 1 (4%) 
Area (mm2) ND ∗∗
Median 978 799 
Mean 1439 1473 
Range 169–6365 144–7043 
ND (No Difference) 
∗ Pearson chi-square-test 
∗∗ Mann-Whitney U test 
Table 2 Results: remission rate, adverse effects and number of given injections. 
TAC n = 25 5-FU n = 24 p ∗
n % n % 
Remission 
15 60 11 46 > 0.05 
Number of injections n (%) > 0.05 
1 2 8 1 4 
2 10 40 10 42 
3 13 52 13 54 
Adverse effects 
Skin atrophy 11 44 2 8 < 0.05 
Telangiectasia 14 50 5 21 < 0.05 
∗ chi-square test 
 
 
 
 
 
 
 
 
 
 
 
 
 
 of the POSAS scale at each visit. With spectrocutometry,
the estimated hemoglobin concentration of the keloid was
calculated as described in previous study. 14 
At the ﬁrst three visits, a 3 mm punch biopsy was ob-
tained from the active border of the keloid for histolog-
ical and immunohistochemical analyses. The ﬁrst biopsy
was obtained before any treatment was given. The second
and third biopsies were obtained after the ﬁrst and secondinjections at 4 and 8 weeks respectively. Blood vessel den-
sity was analyzed by counting blood vessels (CD31) and ﬁ-
broblast proliferation was evaluated by Ki-67 staining from
the biopsy samples. 
The primary endpoint of the study was remission of the
keloid at 6 months after treatment; secondary endpoints in-
cluded the POSAS score, local adverse effects, blood vessel
density, estimated change in the hemoglobin concentration
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Tnd ﬁbroblast proliferation. The remission of the keloid was 
eﬁned clinically by the blinded observer as ﬂattening of 
he keloid to the degree where no further injections were 
easible or needed. Same blinded observer did the conclu- 
ions of possible occurred side effects, skin atrophy and 
elangiectasia. 
mmunohistochemical (IHC) staining 
iopsy samples of keloids were collected and ﬁxed with 
% paraformaldehyde and embedded in parafﬁn accord- 
ng to standard protocols. Hematoxylin/eosin staining and 
mmunohistochemical staining (IHC) was performed from 
- μm thick parafﬁn sections as previously described. 15,16 
rieﬂy, Formalin ﬁxed, parafﬁn-embedded tissue sections 
ere deparafﬁnized, processed with appropriate antigen re- 
rieval solution (10 mM Tris-HCL, 1 mM EDTA, pH 9), incu-
ated with the blocking reagent (10% normal goat serum, 
% non-fat milk and 5% BSA), and endogenous peroxidase 
ctivity was suppressed with hydrogen peroxide. Tissue sec- 
ions were incubated with the primary antibody overnight 
t 4 °C. The rat anti-CD31 (clone 550,274) and rat anti-Ki67
clone M7249 TEC-3) antibodies were used for IHC (both 
D Pharmingen, Oxford, UK) followed by the appropriate 
orseradish peroxidase-conjugated (HRP) secondary anti- 
odies. 15 The blocking reagents used for IHC were S2O23 
EAL and S0809 Antibody Diluent (DakoCytomation). The 
eroxidase reactive chromogen used was 3.3 diaminobenzi- 
ine (DAB; K3465,DAKO, Agilent Technologies). Each stain- 
ng experiment included sections stained without primary 
ntibody as negative controls. 
uantitative analysis of immunostaining and 
istochemical staining 
mage analysis as well as the quantiﬁcation of histological 
nd immunohistochemical (IHC) parameters were done 
sing Spectrum digital pathology system (Aperio Technolo- 
ies). 15 –17 Brieﬂy, all histological slides were scanned to 
igital microscope using the Aperio ScanScope® CS and XT 
ystems (Aperio Technologies Inc., Vusta CA, USA). 17 Slides 
ere viewed and analysed remotely using desktop personal 
omputers employing the web-based ImageScope TM viewer. 
he Spectrum digital pathology system analysis algorithm 
ackage and Image Scope analysis software (version 9; 
perio Technologies Inc.) was used to quantify the IHC 
ignal. The Aperio-software separates the signal from the 
hromogen and hematoxylin/eosin by a color deconvolution 
ethod to identify negative and positive cells/areas. Cus- 
om made algorithms were generated for each respective 
taining. The software was used to calculate the area of
ositive and negative staining, the average positive inten- 
ity (optical density), and graded as weak (1 + ), medium
2 + ), and strong (3 + ) positive staining. 17 The quantiﬁed
istochemical analysis of CD31- and Ki-67stainings were 
erformed according to the protocols used to establish 
hese algorithms for each type of stain. 15,17 At least 5 000
ells (or entire keloid biopsy for CD31) were counted for
ach measurement from each sample. All evaluations were 
ossible were performed in an unbiased blinded fashion .e, the examiner did not know which group (TAC/5-FU) the
pecimens belonged. 
tatistical analysis 
tatistical analyses were performed with SPSS version 21.0 
oftware IBM SPSS Statistics for Windows. (Version 21.0. Ar-
onk, NY: IBM Corp.) 
For comparison of patient characteristics between the 
AC and 5-FU group, the chi-square (discrete variables) test
nd Mann-Whitney U test (continuous variables) were used. 
he frequency of side effects was analyzed with a chi-
quare test. A paired t -test was used for comparisons be-
ween the baseline and post-treatment values of CD31, Ki-
7, hemoglobin concentration and POSAS scores. A P-value 
ess than 0.05 was considered statistically signiﬁcant. 
esults 
ne patient dropped out from the 5-FU group after the ﬁrst
isit, because the patient decided against keloid treatment. 
lso, one patient with two keloids in the 5-FU group dis-
ontinued the treatment due to a local allergic reaction to
he second 5-FU injection, comprising of urticaria and lo-
al blistering that resolved after a day and required no ad-
itional treatment. For the ﬁnal analysis, the 5-FU group
omprised of 24 keloids and TAC group comprised of 25
eloids. The clinical characteristics of the patients in the
wo groups were comparable ( Table 1 ). In the TAC group a
otal of 61 injections were given and the mean dosage was
.4 mg ( ± 5.4 mg, range 1–35 mg) and the mean number of
njections were 2.4 (range 1–3), whereas in the 5-FU group
 total of 60 injections were given with a mean dosage of
5 mg ( ± 13 mg range 7.5–50 mg) and the mean number of
njections were 2.4 (range 1–3). 
Treatment efﬁcacy did not differ signiﬁcantly between 
he two groups. The remission rate at 6 months was 46% in
he 5-FU group compared to 60% in the TAC group (p > 0.05).
linically, ﬂattening and softening of the keloids was no-
iced after both 5-FU and TAC injections in keloids respond-
ng to the treatment ( Figure 1 ). Skin atrophy was seen in
4% of the patients in the TAC group and in 8% of the pa-
ients in the 5-FU group ( Table 2 ). The difference was sta-
istically signiﬁcant (p < 0.05). Also telangiectasia was seen 
n 50% of the patients in the TAC group and in 21% of the
atients in the 5-FU group (p < 0.05). The evaluation of side
ffects was performed by unmagniﬁed clinical observation 
or both telangiectasia and skin atrophy. The POSAS scores 
Observer and Patient) decreased in both the 5-FU and the
AC groups during the 6 months follow-up ( Figure 2 ). The
OSAS evaluation (observer and patient) between baseline 
nd 6 months was improved (p < 0.05) in both groups, how-
ver there was no difference seen between the two treat-
ent groups. The estimated hemoglobin concentration had 
ecreased at 6 months compared to the baseline in the
AC group (0.17 ± 0.18 and 0.10 ± 0.18, p < 0.05). In the
-FU group, the estimated haemoglobin concentration at 
 months did not signiﬁcantly change from the baseline
alue (0.13 ± 0.10 and 0.10 ± 0.09, (p > 0.05) ( Figure 3 ).
he blood vessel density (deﬁned as CD31-positive area) 
8 K. Hietanen et al. 
Figure 1 Example of a keloid treated with 5-FU injections be- 
fore (a) and after (b) treatment and another keloid treated with 
TAC injections before (c) and after (d) treatment. Both keloids 
shown here were in remission in the end of the 6 months follow- 
up. The small comedo in A and B is unrelated to treatment. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2 (A) POSAS Observer scores in the 5-FU and TAC 
groups. (B) POSAS Patient scores in the 5-FU and TAC groups. 
Figure 3 Hemoglobin (Hb) concentration at each visit, mea- 
sured from the entire scar area by means of standardized digi- 
tal imaging and spectrocutometry. Hb concentration in the scar 
is shown as blood haemoglobin index. 
 
 
 
 
 
 
 
 decreased in the entire 49- keloid group, but in the 5-FU
group, the change was not signiﬁcant (p > 0.05) ( Figures 4
and 5 ). In the TAC group, the blood vessel density signiﬁ-
cantly decreased from baseline value (p < 0.05). The reduc-
tion in blood vessel density measured supported the ﬁndings
that a reduction of estimated hemoglobin concentration in
keloids analyzed with spectrocutometry ( Figures 3 –5 ). 
Ki-67 values were analyzed from the whole keloid area
reticular dermis excluded. The mean proliferation rate were
9.9% (range 3.3–16.3) at baseline and 12.1% (range 6.4–21.2)
after treatment in the 5-FU group whereas the mean pro-
liferation rates in the TAC group were 11.3% (range 1.9–
25.3) at baseline and 7.9% (range 1.7–24.7) after treat-
ment. The difference before and after treatment was  statistically signiﬁcant in both groups, but in the 5-FU group
proliferation rate was increased by the treatment (p < 0.05)
and in the TAC group it decreased (p < 0.05) ( Figures 5
and 6 ). 
Discussion 
Treating keloids with TAC injections has been common
practice since the 1970s. 1,3 , 4 Keloid treatment with 5-FU,
however, is still considered as experimental although few
randomized controlled trials have studied the effects of
5-FU treatment on keloid scars. Nanda et al. and Kon-
tochristopoulos et al. published a series of patients treated
Treatment of keloid scars with intralesional triamcinolone 9 
Figure 4 Blood vessel density before and after treatment in 5- 
FU and TAC groups . The keloids were treated with either TAC or 
5-FU injections in a randomized controlled trial. The blood ves- 
sels were determined from the tissue biopsies obtained from 
the keloids before and after the treatment. Tissue sections 
were stained by antibody against endothelial cells (CD31) and 
quantitative digital pathology analysis of scanned slides was 
performed. The results are expressed as the area covered by 
the blood vessels in the total keloid area in the biopsy. 
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Figure 5 Immunohistochemical stainings for CD31 and Ki-67 
before (left column) and after (right column) treatment in 5- 
FU and TAC groups. Positive endothelial cells (CD31) and stro- 
mal cell nuclei (Ki-67) marked by arrowheads. Vascular density 
measured by CD31 decreased signiﬁcantly in the TAC group but 
not in the 5-FU group. Proliferation rate measured by Ki-67 de- 
creased signiﬁcantly in the TAC group and increased in the 5-FU 
group. The scale bar in the lower right corner measures 200 
μm. 
Figure 6 Cell proliferation rates at baseline and post- 
treatment. The keloids were treated with either TAC or 5-FU 
injections in a randomized controlled trial. Skin biopsies were 
obtained from the edges of keloids before and after the treat- 
ment. Biopsies were ﬁxed and processed for IHC staining of 
proliferating nuclei by using an antibody against Ki67, a well- 
established proliferation marker. Quantitative digital pathology 
analysis of scanned slides was performed. The results are ex- 
pressed as the percentage of proliferating cells in total keloid 
cell population. ith 5-FU alone. 18,19 Both of these studies reported favor- 
ble outcomes, with a 70 to 95% success rate. Neither of
hese studies, however, was a randomized controlled trial. 
adeghinia et al. conducted a randomized controlled trial 
ith 44 patients comparing the efﬁcacy of 5-FU and TAC in-
ections. 11 Their study was similar to ours in terms of sample
ize, injection rate and concentrations and dosages used. 
adeghinia et al. graded the overall improvement using a 
-point scale. 11 Both patient reported outcome and assess- 
ent by the observer indicated that 5-FU injections pro- 
uced signiﬁcantly better results compared to TAC injec- 
ions. We found no signiﬁcant difference in the efﬁcacy of
he two treatments in the present study. We observed a pos-
tive response in both the TAC and the 5-FU groups, and the
mprovement between the baseline and 6 months that was 
tatistically signiﬁcant in both groups. However, remission 
ate after 5-FU treatment was lower than in previous stud-
es mentioned above and although there was a signiﬁcant 
ffect of 5-FU injections, less than half of the patients in
his study were in remission after 5-FU treatment. 
In our study permanent local side effects were more 
ommon in the TAC group than in the 5-FU group. The side
ffects of TAC injections have been reported also in pre-
ious trials. Sadeghia et al. reported no side effects in ei-
her group; Nanda et al. reported ulceration in 21.4% and 
urning sensation in 7.1% at the 5-FU treatment sites. 11,18 
owever, TAC treatment was associated with signiﬁcant lo- 
al side effects in other reports. 1,2 , 20,21 Fitzpatrick and Hau- 
ani et al. reported their experiences with 5-FU injections 
or hypertrophic scarring, and observed no systemic or local 
dverse effects. 9,22 On the other hand Kontochristopoulos 
t al. reported that all 20 of their patients found the in-
ections painful and 30% presented with superﬁcial ulcera- 
ions in their keloids after 5–FU injections. 19 The same study 
howed that all 20 patients developed hyperpigmentation 
t the treatment sites, but this did not cause any signif-
cant cosmetic morbidity and gradually subsided. 19 Srivas- 
ava et al. studied TAC, 5-FU and their combination in keloid
reatment in a randomized parallel group study with 60 pa-
ients. 12 They stated that TAC, 5-FU and their combination 
re all effective in keloid treatment, but the combination 
10 K. Hietanen et al. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 treatment of TAC and 5-FU was superior in efﬁcacy and inci-
dence of side effects. 12 Srivastava et al. reported skin ulcer-
ation in 9 patients of their 20 patients in the 5-FU group( 12 .
Contrary to their ﬁndings our side effect proﬁle was low. In
our study, one patient developed a local allergic reaction
and skin blistering after the second injection of 5-FU, which
resulted in discontinuing the treatment. This was the only
immediate local side effect in this study and it is not clear
why this occurred and whether it was the cytotoxic effect
that caused the ulceration. 
Three patients exhibited hyperpigmentation in the 5-FU
group. The TAC group presented with signiﬁcantly more per-
manent local adverse effects 44% with skin atrophy and 50%
with telangiectasia compared to 8% and 21% in the 5-FU
group respectively. This observation may support the role of
5-FU over TAC especially in cosmetically important areas,
where local adverse effects may lead to considerable aes-
thetic problems. However clear conclusion cannot be drawn
from this limited study. A greater number of patients re-
cruited to this study would be needed to provide a more ac-
curate side effect proﬁle. Another trial comparing TAC and
TAC + 5-FU may provide some insight into the added efﬁcacy
combinatorial therapy may offer. 
We have shown that the vascularity of a keloid may be
reduced by TAC injections as shown by decreased blood ves-
sel density and estimated keloid hemoglobin concentrations
through spectrocutometry assessment. Increased vascular-
ity is reported in both keloids and hypertrophic scars and
is an indicator of ongoing metabolic scar activity. 23,24 Our
ﬁnding that hemoglobin concentration in keloids deﬁned
by spectrocutometry correlates with actual blood vessel
density may further encourage the use of spectrocutometry
as an objective assessment method in scar treatment. In
our study vascular density in keloids were not signiﬁcantly
changed following 5-FU injections. Also Kontochristopoulos
et al. found vascularity to be slightly decreased after 5-FU
treatment. 19 Their ﬁnding, however, was not veriﬁed with
IHC. Studies have shown TAC treatment may decrease
sprouting angiogenesis. 25,26 Further studies need to be
performed to validate the sensitivity and speciﬁcity of
these modalities in scar outcomes. 
Kontochristopoulos et al. also studied the proliferation
rate of ﬁbroblasts with Ki-67. 19 They reported a decrease
(1–5% to 0.5–2%) in Ki-67 in all their 10 cases after 6 5-FU in-
jections treatment. However, we examined 24 5-FU treated
keloids before and after 1–3 injections treatment and found
that the level of Ki-67 increased in the 5-FU group, and de-
creased in the TAC group. This may warrant further investi-
gation into the action pathways of 5-FU in keloid treatment.
The weakness of our study is there was a short 6 months
follow-up time, which is not long enough to observe for
keloid recurrence, which can occur as late as 24 months
or more after treatment. More modalities of assessment
would have strengthened this study however we do provide
some preliminary data that suggest the efﬁcacy of TAC and
5-FU are similar but not dramatically different. One can
see that these treatments usually show some beneﬁt after
3–4 injections, however if no response is seen, it is not
recommended to continue with the same line of treatment.
Where beneﬁts were not seen, patients from this study
went on to have surgery and radiotherapy, and some had
further substance injections (TAC, 5-FU or verapamil) aswell as pressure garment or silicone gel sheeting. This is a
limited study for this reason and does not aim to challenge
the efﬁcacy of other well studied modalities but focuses
on comparing TAC to 5-FU in there role as early minimally
invasive treatment modalities. 
Conclusion 
5-FU injections are effective in some patients when as-
sessed clinically, but showed no clear clinical beneﬁt over
TAC. TAC injections may lead to better remission rate than
5-FU injections, with slightly more local adverse effects
such as skin atrophy and telangiectasia, but there was no
statistically signiﬁcant difference in this study in remission
rate between the two therapies. A signiﬁcant number of pa-
tients do not respond to either of the two injection treat-
ments, hence progressing them through to other strategies
would seem reasonable after a six month trial of injectable
therapies. 
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